The autonomous control of polyglycine chain length by TTLL10 inhibition could be exploited to engineer microtubules with specific glycylation patterns for in vitro studies or therapeutic applications. By manipulating the levels of TTLL10 and other glycylation enzymes, researchers could generate microtubules with tailored glycylation patterns, allowing for the study of how different glycylation states affect microtubule function and interactions with cellular effectors. These engineered microtubules could serve as valuable tools for investigating the role of glycylation in cellular processes, such as cilia maintenance, cell division, or intracellular transport. Moreover, understanding the mechanisms that control polyglycine chain length could lead to the development of novel therapeutic strategies targeting tubulin modifications for the treatment of diseases associated with dysregulated microtubule dynamics.